Deucravacitinib Shows Consistent Efficacy in Psoriasis Treatment: Study Dr. Shravani Dali21 Feb 2025 8:30 PM ISTResearchers have found in a new study that deucravacitinib effectively reduces Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality...
JAMA Study Finds Deucravacitinib Effective and Safe for Psoriasis Patients Jacinthlyn Sylvia9 Dec 2024 8:00 PM ISTThis recent 3-year study revealed that deucravacitinib which is an oral treatment for moderate to severe plaque psoriasis to offer a sustainable and...
Deucravacitinib Found to Be Safe and Effective for Psoriasis Over 3 Years: JAMA Dr Riya Dave5 Dec 2024 8:15 PM ISTResearchers have found that deucravacitinib for long-term treatment is well tolerated and has a sustained clinical response in the management of...
BMS Gets CDSCO Panel Nod to Study Deucravacitinib Dr. Divya Colin20 May 2024 6:00 PM ISTNew Delhi: The drug major BMS has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Deucravacitinib improves outcomes in patients with psoriasis arthritis: Study Jacinthlyn Sylvia1 April 2024 1:45 AM ISTPsoriatic arthritis is a chronic and debilitating autoimmune disease which leads to significant physical disability and diminished quality of life....
Deucravacitinib safer and more effective than apremilast for treating moderate to severe scalp psoriasis Dr. Shravani Dali2 Feb 2024 9:45 AM ISTDeucravacitinib is safer and more effective than apremilast for the treatment of moderate to severe scalp psoriasis suggests a new study published in...
Bristol Myers Squibb Sotyktu long term data demonstrate durable efficacy, consistent safety for up to 3 years in moderate-to-severe Plaque Psoriasis Ruchika Sharma12 Oct 2023 12:50 PM ISTPrinceton: Bristol Myers Squibb has announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu...
Bristol Myers Squibb Sotyktu gets European Commission nod for adults with plaque psoriasis Ruchika Sharma30 March 2023 1:24 PM ISTSotyktu is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small...
Deucravacitinib treatment beneficial for patients with active lupus: Study Dr. Kamal Kant Kohli14 Nov 2022 7:45 PM ISTUSA: A recent study in Wiley's Arthritis & Rheumatology has shown promising results for deucravacitinib in patients with active lupus....
Bristol Myers Squibb bags USFDA approval for plaque psoriasis oral treatment Sotyktu Ruchika Sharma12 Sept 2022 1:29 PM ISTPsoriasis is a widely prevalent, chronic, systemic immune-mediated disease.
Deucravacitinib, a novel cure for patients with active SLE Dr. Hiral patel7 Jun 2022 12:00 PM ISTAustralia: Deucravacitinib (DEUC) showed statistically significant and sustained clinical efficacy and safety in patients with active systemic lupus...
Deucravacitinib beneficial in Moderate-to-Severe Plaque Psoriasis: Study Dr. Shravani Dali28 Feb 2022 9:00 AM ISTDeucravacitinib is beneficial in Moderate-to-Severe Plaque Psoriasis, according to a recent study published in the Dermatology and Therapy ...
